Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
Top Page
Nanobiotix
(NASDAQ:NBTX)
41Neutral
Positive Factors
Clinical Collaboration
NBTX is collaborating with MD Anderson Cancer Center to explore the potential of NBTXR3 in a range of additional tumor types, including locally advanced or borderline resectable pancreatic cancer, inoperable locoregionally recurrent NSCLC, esophageal cancer, and other tumors.
Strategic Partnerships
The management team highlighted a well-defined pathway for the development of nanoprimers and potential partnerships with several material transfer agreements already in progress.
Negative Factors
Financial Stability Concerns
Investor focus will largely remain on the company's cash runway and the ongoing Phase III NANORAY-312 study, indicating concerns about financial stability.
Nanobiotix (NBTX) vs. S&P 500 (SPY)
Market Cap
$153.45M
Dividend YieldN/A
Average Volume (3M)9.59K
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue GrowthN/A
EPS Growth54.68%
CountryUS
Employees102
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding47,133,327
10 Day Avg. Volume11,552
30 Day Avg. Volume9,587
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.50Price Target Upside13.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nanobiotix Business Overview & Revenue Model
Company DescriptionNanobiotix (NBTX) is a late-stage clinical biotechnology company focused on developing nanomedicine products to treat cancer. The company specializes in the application of nanophysics to medicine, particularly through its proprietary technology platform, NanoXray. This platform's lead product candidate, NBTXR3, is designed to enhance the efficacy of radiotherapy in cancer treatment by activating the physical properties of nanoparticles to increase radiotherapy energy absorption within tumor cells.
How the Company Makes MoneyNanobiotix makes money primarily through the development and commercialization of its lead product candidate, NBTXR3, which is undergoing clinical trials for various cancer indications. Revenue streams are expected to include licensing agreements, collaborations with pharmaceutical companies, and sales of the product once it gains regulatory approval. The company may also receive milestone payments and royalties from these partnerships. Furthermore, research and development grants and funding from public and private entities contribute to its financial resources. Significant partnerships with institutions and companies in the healthcare and biotechnology sectors are crucial in advancing its clinical programs and facilitating market access.
Nanobiotix Financial Statement Overview
Summary
Nanobiotix shows significant revenue growth but remains unprofitable with ongoing operational challenges. The balance sheet is strained with negative equity, and the company relies on external financing. Improvements in cash flow management are a positive sign, but financial stability remains a concern.Income Statement
Nanobiotix shows substantial revenue growth with a 529.5% increase from the previous year, indicating strong top-line improvement. However, the company remains unprofitable with a negative net profit margin of -132.1% and an EBIT margin of -89.1%, reflecting ongoing operational challenges. The gross profit margin is healthy at 100%, but the overall profitability is affected by high operating expenses.45
Neutral
Balance Sheet
The company's balance sheet is strained with a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity, but the total debt position is substantial. The equity ratio is negative, further highlighting risks in financial leverage and solvency.30
Negative
Cash Flow
Nanobiotix's cash flow shows improvement in free cash flow with a growth rate of 65.6%, suggesting better cash management. However, the operating cash flow remains negative, indicating continued reliance on external financing to support operations. The free cash flow to net income ratio is not calculable due to negative values.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 58.66M | 36.21M | 4.78M | 10.00K | 50.00K | 68.00K | Gross Profit |
| 58.66M | 36.21M | 3.79M | 10.00K | 50.00K | 68.00K | EBIT |
| -24.49M | -26.78M | -46.70M | -52.58M | -36.43M | -46.78M | EBITDA |
| -21.12M | -23.69M | -45.15M | -45.60M | -31.49M | -44.77M | Net Income Common Stockholders |
| -39.27M | -39.70M | -57.04M | -47.00M | -33.62M | -50.91M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 75.28M | 75.28M | 41.39M | 83.92M | 119.15M | 35.09M | Total Assets |
| 93.90M | 93.90M | 59.77M | 101.77M | 134.03M | 56.20M | Total Debt |
| 50.56M | 50.56M | 53.17M | 46.02M | 48.98M | 44.53M | Net Debt |
| -24.72M | -24.72M | 11.78M | -37.90M | -70.17M | 9.43M | Total Liabilities |
| 95.74M | 95.74M | 86.81M | 74.98M | 63.56M | 58.11M | Stockholders Equity |
| -1.84M | -1.84M | -27.05M | 26.79M | 70.47M | -1.91M |
| Cash Flow | Free Cash Flow | ||||
| 866.00K | -12.81M | -37.20M | -30.11M | -27.64M | -42.61M | Operating Cash Flow |
| 1.36M | -12.48M | -37.10M | -29.87M | -27.54M | -41.17M | Investing Cash Flow |
| -533.00K | -349.00K | 138.00K | -242.00K | -112.00K | -1.46M | Financing Cash Flow |
| 70.71M | 46.77M | -5.65M | -5.18M | 111.77M | 41.49M |
Nanobiotix Technical Analysis
Negative
3.08
Price Trends
3.39
Negative
3.63
Negative
4.48
Negative
Market Momentum
-0.09
Positive
35.91
Neutral
14.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBTX, the sentiment is Negative. The current price of 3.08 is below the 20-day moving average (MA) of 3.66, below the 50-day MA of 3.39, and below the 200-day MA of 4.48, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 35.91 is Neutral, neither overbought nor oversold. The STOCH value of 14.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NBTX.
Nanobiotix Risk Analysis
Nanobiotix disclosed 72 risk factors in its most recent earnings report. Nanobiotix reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nanobiotix Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $5.90B | 268.98 | 12.21% | ― | 40.80% | 100.62% | |
50 Neutral | $95.61M | ― | -101.50% | ― | 76.24% | 38.67% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
41 Neutral | $153.45M | ― | 2152.93% | ― | ― | 54.68% | |
37 Underperform | $166.31M | ― | 123.38% | ― | -42.30% | -9.33% | |
34 Underperform | $99.09M | ― | -216.24% | ― | ― | 61.97% | |
32 Underperform | $9.35M | ― | 234.90% | ― | ― | 46.67% |
* Healthcare Sector Average
Performance Comparison
NBTX
Nanobiotix
3.08
-3.27
-51.50%
TGTX
TG Therapeutics
37.55
21.82
138.72%
IMUX
Immunic
1.10
-0.23
-17.29%
BCLI
Brainstorm Cell Therapeutics
1.64
-3.32
-66.94%
CLLS
Cellectis SA
1.25
-1.31
-51.17%
ADCT
ADC Therapeutics
1.72
-2.18
-55.90%
Nanobiotix Earnings Call Summary
Earnings Call Date: Nov 6, 2024 | % Change Since: -29.36% | Next Earnings Date: Mar 13, 2025
Earnings Call Sentiment Neutral
The earnings call presented a generally positive outlook with significant achievements in collaboration with Janssen and advancement in clinical trials. However, challenges remain with extended timelines for critical trials and the necessity for additional funding. The strategic development of new platforms adds a forward-looking positive aspect to the company's trajectory.Highlights
Strong Cash Position
Announced a first quarter 2024 unaudited cash balance of EUR 58.9 million and reaffirmed cash runway into Q3 2025.
Significant Progress with Janssen Collaboration
Achieved significant progress in the Janssen collaboration for NBTXR3, including a $20 million milestone payment and positive developments in regulatory and manufacturing processes.
Advance in NANORAY-312 Trial
Positive top line data from the expansion part of the Study 102 for NBTXR3, leading to protocol amendments in the NANORAY-312 pivotal Phase III trial.
New Platforms Development
Introduced Curadigm and Oocuity platforms, aiming to expand nanoparticle-based therapy in healthcare.
Lowlights
Extended Timeline for NANORAY-312
The interim analysis for the NANORAY-312 trial is now expected in H1 2026, which is a delay from original plans.
Need for Additional Funding
The company acknowledged the need for additional funding to finance operations and new indications, highlighting financial challenges.
Company Guidance
During the Nanobiotix Q1 2024 earnings call, the company provided guidance on its financial and strategic progress, highlighting several key metrics. Nanobiotix reported an unaudited cash balance of EUR 58.9 million and reaffirmed its cash runway into Q3 2025. The company also highlighted a $20 million milestone payment received from Janssen, part of a collaboration potentially worth more than $2.5 billion plus royalties. This partnership aims to expand the global potential of their lead therapeutic candidate, NBTXR3, across various solid tumor indications. Additionally, Nanobiotix discussed the ongoing pivotal Phase III NANORAY-312 trial, which is evaluating NBTXR3 for elderly patients with locally advanced head and neck cancer. They also plan a randomized Phase II study for Stage 3 non-small cell lung cancer. The transfer of the NANORAY-312 trial sponsorship to Janssen is expected to facilitate global commercialization efforts. Furthermore, the company is exploring expansion opportunities in additional cancer settings and developing two additional nanoparticle platforms, Curadigm and Oocuity, with updates expected in the second half of 2024.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.